Skip to content
The Peptide Effect
Dosage Guide

KPV Dosage Guide: Anti-Inflammatory Protocol

Educational reference covering KPV tripeptide dosage protocols for gut, systemic, and topical anti-inflammatory applications. Dosing information discussed in published research literature for informational purposes only.

View KPV profile →

Medical Disclaimer

This guide is for educational and informational purposes only. It is not medical advice. Dosages described reflect ranges discussed in published research and clinical practice literature — they are not recommendations. Always consult a licensed healthcare provider before using any peptide. Legality and availability vary by jurisdiction.

Overview

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide with well-documented anti-inflammatory properties. Research literature has described KPV as retaining the potent anti-inflammatory activity of the full-length alpha-MSH molecule while lacking its melanogenic (skin-darkening) effects. The anti-inflammatory mechanism is reported to involve inhibition of NF-kB signaling, a master transcription factor that drives the expression of pro-inflammatory cytokines. A notable characteristic of KPV discussed in research is its stability in the acidic environment of the stomach, which provides oral bioavailability — a rare property for peptides, most of which are degraded in the gastrointestinal tract. This acid stability has made KPV a subject of interest in inflammatory bowel disease (IBD) research, where oral delivery directly to the inflamed gut mucosa is therapeutically relevant.

Dosing Protocols

Oral Protocol for Gut Inflammation

Route: Oral (capsule or solution)
Dose: 200–500 mcg
Frequency: 1–2 times daily
Duration: 4–8 weeks, with reassessment

KPV's unusual stability in gastric acid allows for oral administration, which delivers the peptide directly to the gut mucosa. This is the most commonly discussed route for inflammatory bowel conditions. Taking on an empty stomach may optimize mucosal contact. Starting at the lower end of the dose range is commonly discussed.

Subcutaneous Protocol for Systemic Inflammation

Route: Subcutaneous injection
Dose: 200–500 mcg
Frequency: Once daily
Duration: 4–8 weeks

Subcutaneous administration is discussed for systemic anti-inflammatory effects beyond the gastrointestinal tract. This route bypasses first-pass metabolism and provides more consistent systemic bioavailability. The dose range is similar to oral dosing, though some protocols discuss starting at the lower end for injectable use.

Topical Protocol for Skin Conditions

Route: Topical application (cream or gel)
Dose: 0.1–0.5% concentration
Frequency: Applied to affected area 2 times daily
Duration: As needed, typically 4–8 weeks for assessment

Topical KPV formulations have been discussed in dermatological research contexts for inflammatory skin conditions. The anti-inflammatory properties of alpha-MSH fragments on skin have been studied in the context of dermatitis, psoriasis, and wound healing. Custom compounding is typically required for topical preparations.

Reconstitution & Storage

Vial sizes5 mg lyophilized powder per vial (for injectable or oral solution use)
Recommended water volume1 mL bacteriostatic water (BAC water) per vial, yielding 5 mg/mL (5,000 mcg/mL)
StorageStore unreconstituted vials refrigerated at 2–8 °C (36–46 °F). Oral capsule formulations may be stored at room temperature per manufacturer specifications.
Stability once reconstitutedReconstituted injectable solution should be refrigerated and used within 28 days. KPV is reported to be relatively stable as a tripeptide. Oral capsule formulations typically have longer shelf lives.

Use our reconstitution calculator to determine exact syringe units for your dose.

Cycle Guidance

KPV dosing protocols vary depending on the route of administration and the condition being addressed. For gut inflammation, courses of 4–8 weeks are commonly discussed, with reassessment of symptoms before continuing. Some practitioners discuss ongoing low-dose maintenance for chronic inflammatory conditions. For systemic anti-inflammatory use via subcutaneous injection, 4–8 week courses with periodic breaks are frequently referenced. Unlike some other peptides, KPV is not typically discussed in the context of tolerance development, though the long-term effects of continuous NF-kB modulation have not been thoroughly studied in humans. The tripeptide's favorable safety profile in the published literature has led some protocols to discuss extended use, but periodic reassessment remains prudent.

Stacking Considerations

  • KPV is frequently discussed alongside BPC-157 for comprehensive gut healing protocols, as BPC-157 targets tissue repair mechanisms while KPV addresses inflammatory signaling. This combination is one of the most commonly referenced peptide stacks for gastrointestinal health.
  • Combination with thymosin alpha-1 has been discussed for immune-inflammatory conditions where both immune modulation and direct anti-inflammatory effects are desired.
  • For skin conditions, topical KPV has been discussed alongside GHK-Cu (copper peptide) for combined anti-inflammatory and tissue-remodeling effects.
  • Concurrent use with conventional anti-inflammatory medications (NSAIDs, corticosteroids) has not been well studied, and the interaction profile remains uncharacterized.
  • Some protocols discuss combining oral KPV with probiotics and other gut-supportive interventions for comprehensive inflammatory bowel management.

Potential Side Effects

  • Injection site reactions (mild redness, transient discomfort) — for subcutaneous administration
  • Mild gastrointestinal discomfort — reported infrequently with oral administration
  • Headache — reported rarely in user accounts
  • Skin irritation at application site — for topical formulations, particularly in individuals with sensitive or compromised skin barrier
  • The published safety data on KPV specifically is limited, though alpha-MSH fragments as a class have been associated with a favorable safety profile in preclinical and early clinical studies
  • Unlike full-length alpha-MSH or its analogs (e.g., melanotan), KPV is not reported to cause skin darkening (hyperpigmentation)

Contraindications & Cautions

  • Known hypersensitivity to KPV or alpha-MSH-related peptides
  • Active infection requiring antibiotic therapy — NF-kB inhibition could theoretically impair the inflammatory response needed to fight infection
  • Immunosuppressed individuals — the effects of additional anti-inflammatory modulation in immunocompromised states have not been characterized
  • Pregnancy and breastfeeding — no safety data available in these populations
  • Severe hepatic impairment — metabolism and clearance have not been studied
  • Concurrent use of immunosuppressive medications — potential for additive immune-modulating effects

Related

KPV Profileinflammationgut healthskin healthimmune systembpc-157 dosagethymosin-alpha-1 dosage

References

  1. Anti-inflammatory peptide KPV exerts anti-inflammatory effects in intestinal epithelial cells via inhibition of NF-kappaB (2003) — PubMed
  2. Alpha-MSH and related peptides: biochemistry and anti-inflammatory properties (2007) — PubMed
  3. alpha-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo (2009) — PubMed
  4. Neuropeptides and skin inflammation: the role of alpha-melanocyte-stimulating hormone in cutaneous immunity (1999) — PubMed

Frequently Asked Questions

Can KPV be taken orally, and does it survive stomach acid?
Yes, KPV is one of the few peptides discussed in research literature as having oral bioavailability. As a tripeptide (just three amino acids), it has unusual stability in the acidic environment of the stomach. This property makes it particularly suited for inflammatory bowel conditions, as oral administration delivers the peptide directly to the inflamed gut mucosa. Published research by Brzoska and colleagues has demonstrated anti-inflammatory effects of KPV in intestinal epithelial cell models.
How does KPV differ from melanotan or other alpha-MSH analogs?
KPV is a C-terminal fragment of alpha-MSH consisting of only three amino acids (Lys-Pro-Val). Unlike full-length alpha-MSH or analogs such as melanotan II, KPV retains anti-inflammatory activity but does not activate melanocortin receptors (MC1R) responsible for skin darkening. This makes KPV specifically an anti-inflammatory peptide without the tanning, appetite-suppression, or sexual function effects associated with other melanocortin system peptides.
What conditions is KPV most commonly discussed for?
KPV is most frequently discussed in the context of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, due to its oral bioavailability and NF-kB inhibition in intestinal tissue. It is also discussed for inflammatory skin conditions (dermatitis, psoriasis), systemic inflammatory states, and as part of broader gut health protocols. Research has focused on its ability to reduce pro-inflammatory cytokine production in intestinal epithelial cells.
How long does KPV take to show anti-inflammatory effects?
The timeline for noticeable effects varies by condition and route of administration. For gut inflammation, some individuals report improvements in symptoms within 1–2 weeks of consistent oral dosing, while others describe a more gradual response over 4–6 weeks. The anti-inflammatory mechanism (NF-kB inhibition) acts at the cellular signaling level, and the downstream effects on tissue inflammation and symptom resolution may take time to manifest clinically.
Is KPV safe to use alongside BPC-157?
The combination of KPV and BPC-157 is one of the most commonly discussed peptide pairings for gut health in research communities. KPV addresses inflammatory signaling via NF-kB inhibition, while BPC-157 is discussed for its tissue-protective and healing properties. No controlled studies have evaluated this specific combination, but both peptides individually have favorable safety profiles in published preclinical data. Many protocols discuss using them concurrently for complementary gut-healing effects.
Does KPV cause skin tanning like melanotan?
No. KPV does not cause skin darkening. Although it is derived from alpha-MSH (which does have melanogenic activity through the full molecule), the KPV tripeptide fragment does not bind to MC1R melanocortin receptors responsible for melanin production. Its activity is limited to anti-inflammatory effects mediated through NF-kB pathway inhibition. This is an important distinction from full-length alpha-MSH analogs such as melanotan II.